Genmab — November 2019
-
Over dobbelt op af gennemsnitomsætningen de seneste 5 år.
-
-
God morgen
-
-
on relevance of Dara-CyBorD regimen, cost https://twitter.com/MichaelodwyerMD/status/1199333601172586497
https://twitter.com/SyedMAhmedMDPhD/status/1199522038811111424 -
Successful treatment with daratumumab for post‐HSCT refractory hemolytic anemia - posted the abstract before; this is the full article https://sci-hub.tw/https://onlinelibrary.wiley.com/doi/abs/10.1002/pbc.28010?af=R "We suggest that daratumumab may be a valid treatment option
for refractory post-HSCT AIC."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind